Oxygen versus ambient air in patients with intermediate-risk acute pulmonary embolism: The AIR randomized clinical trial

David Jimenez, M.D., Ph.D.
Hospital Ramón y Cajal, Universidad de Alcalá, CIBERES
Madrid, Spain

Reversal of hypoxic vasoconstriction is a potential target for treatment in patients with intermediate-risk pulmonary embolism. The AIR investigators aimed within this pilot trial to assess the effect of oxygen in patients with intermediate-risk PE who did not have hypoxemia at baseline using the variant in the two study groups to be supplemental oxygen versus ambient air. RV/LV was studied at a 48-hour interval, showing some efficacy outcomes improved in the supplemental oxygen group.

Previous Article ISTH announced new editors for its flagship publication, the Journal of Thrombosis and Haemostasis (JTH)
Next Article A common, racially diverse protease activated receptor 4 functional variant impacts ischemic stroke outcomes: evidence for a pharmacogenetic effect